Author details

Full Name

Sarah K Tasian

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37480164	Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.	Pediatr Blood Cancer	2023
35950535	Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against - mutant acute myeloid leukemia and -rearranged acute lymphoblastic leukemia.	Haematologica	2023
38036631	Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.		2023
37944074	Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay.	JCO Precis Oncol	2023
37662410	Human plasma cells engineered to secrete bispecifics drive effective leukemia killing.		2023
37992684	Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.	Cell Rep Med	2023
37725576	Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.	Clin Cancer Res	2023
37645778	Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.	bioRxiv	2023
37634013	Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.		2023
37683180	Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.		2023
37217248	Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.		2023
37021525	Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.		2023
37392046	acute lymphoblastic leukemia: still challenging to cure thirty years later.		2023
37452102	Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.	Leukemia	2023
37381775	<i>ETV6</i> fusions from insertions of exons 3-5 in pediatric hematologic malignancies.	Haematologica	2023
37439336	Down syndrome and leukemia: from basic mechanisms to clinical advances.		2023
36861399	Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023.		2023
37171449	CD38 as a pan-hematologic target for chimeric antigen receptor TÂ cells.	Blood Adv	2023
37489549	Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.	Pediatr Blood Cancer	2023
35112552	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).	Haematologica	2022
36099049	Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.	J Clin Invest	2022
35560156	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.	Blood	2022
36485164	Clinical screening for Ph-like ALL and the developing role of TKIs.	Hematology Am Soc Hematol Educ Program	2022
34193976	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	Leukemia	2022
33375775	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.	Haematologica	2022
34855461	CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.	J Clin Oncol	2022
34840026	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.	Eur J Cancer	2022
35015683	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.		2022
34531250	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.	Journal for ImmunoTherapy of Cancer	2021
32414848	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.	Haematologica	2021
34183059	Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts.		2021
34077953	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia.	Blood	2021
34210682	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.	Clin Cancer Res	2021
33563661	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.	Cancer Discov	2021
34196168	Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.	Haematologica	2021
33761058	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis.	Journal of Clinical Immunology	2021
33098744	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.	Pediatric Blood and Cancer	2021
33357484	Are we ABL to do better for children with BCR-ABL1-like acute lymphocytic leukaemia?	Lancet Haematology,The	2021
34865703	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?	Best Pract Res Clin Haematol	2021
32832663	Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers.	Sci Adv	2020
31851053	The future of cellular immunotherapy for childhood leukemia.	Current Opinion in Pediatrics	2020
32191635	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.	Journal of Clinical Investigation	2020
31935290	Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.	Blood advances	2020
31867817	Transient atypical monocytosis after Î±/Î² T-cell-depleted haploidentical hematopoietic stem cell transplantation.	Pediatric Blood and Cancer	2020
33242441	Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?	Lancet Haematology,The	2020
32688206	Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.	Eur J Cancer	2020
31255796	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.	J Mol Diagn	2019
31770440	Opportunities for immunotherapy in childhood acute myeloid leukemia.	Blood Adv	2019
31808843	Opportunities for immunotherapy in childhood acute myeloid leukemia.	Hematology Am Soc Hematol Educ Program	2019
29884903	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.	Leukemia	2019